Z17.1
Estrogen receptor negative status [ER-]
Clinical Classification Guidelines
Medical Intelligence & Overview
Estrogen receptor negative (ER-) status refers to a characteristic of some breast cancers that do not have receptors for the hormone estrogen. This classification affects how the disease is managed and treated. Identifying ER- status is an important part of diagnosing and planning treatment for breast cancer, as it provides insights into the tumor's behavior and potential treatment options.
Causes & Symptoms
Clinical Causes: Genetic mutations within breast cancer cells Environmental factors influencing gene expression Hormonal influences during cell development Random cellular changes during tumor formation
Key Symptoms: Lump or mass in the breast or underarm Changes in the size, shape, or feel of the breast Nipple discharge other than milk Skin changes on the breast, such as redness or dimpling Persistent pain in the breast or nipple area
Diagnostic & Treatment
Diagnosis Path: Determining ER- status involves biopsy procedures where a sample of breast tissue is examined under a microscope. During this process, laboratory tests are conducted to evaluate the presence or absence of estrogen receptors on the cancer cells. Immunohistochemistry (IHC) testing is commonly used to assess receptor status, helping clinicians classify the tumor as ER- or ER-positive. Additional tests may include imaging studies like mammography, ultrasound, or MRI to evaluate the extent of the disease.
Treatment Protocols: Surgery to remove the tumor or affected breast Chemotherapy to target rapidly dividing cancer cells Radiation therapy to eliminate residual disease post-surgery Targeted therapies that focus on specific genetic markers Clinical trials exploring new treatments for ER- breast cancer
Clinical Advice & FAQs
Billing Guidance
Is Z17.1 a billable ICD-10 code?
Yes, Z17.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.1?
Clinical documentation must specify the nature of Estrogen receptor negative status [ER-] and any associated comorbidities for accurate reporting.
Cite this Clinical Reference